Sunday 25 May 2025

The Pharmaletter

One To Watch

dice_molecules_company

DiCE Molecules

DiCE Molecules is a privately held biotechnology company using directed evolution to power small molecule drug discovery.

DiCE was co-founded in 2013 by Pehr Harbury, the investor of the firm's core technology, Kevin Judice and Phil Patten.

Want to Update your Company's Profile?


Latest DiCE Molecules News

$80 million financing for DiCE Molecules
11 January 2021
Roche and DiCE Molecules enter into drug discovery collaboration
20 December 2017
Sanofi and DiCE Molecules ink collaboration worth as much as $2.3 billion
16 March 2016
More DiCE Molecules news >


Today's issue

The week in pharma: action, reaction and insight – week to May 23
Biotechnology
The week in pharma: action, reaction and insight – week to May 23
25 May 2025
Pharmaceutical
Gilead says Trodelvy ASCENT-03 study meets primary endpoint
24 May 2025
Pharmaceutical
Reshaping HIV – how the journey from daily pills to long-acting therapies could take us closer to ending the HIV epidemic
23 May 2025
Biotechnology
Ionis’ olezarsen shows new promise with strong Phase III results
23 May 2025
Pharmaceutical
Verastem expands ambitions with strong pancreatic cancer data at ASCO
23 May 2025
Pharmaceutical
May batch of novel medicines recommended for approval by CHMP
23 May 2025
Pharmaceutical
MHRA approves Akantior to treat acanthamoeba keratitis
23 May 2025


Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze